thought call
jakafi revenu continu support stock price
await greater clinic progress meaning pipelin asset
give credit continu pipelin execut increas tp
jakafi us sale beat chang view see
littl threat jakafi revenu near term continu believ jakafi
sale gener well appreci consensu estim long-term
guidanc sale remain neutral share
increas tp steadi progress pipelin asset name
ruxolitinib itacitinib gvhd topic ruxolitinib vitiligo capmatinib led
partner novarti provid us greater confid abil
develop asset long term also increas po topic
ruxolitinib posit data vitiligo remaind could
see modest sentiment-driven upsid execut nda submiss
capmatinib pemigatinib data releas itacitinib yet see
larg catalyst potenti fda approv sever asset
could occur along regulatori file data readout asset address
larger market pemigatinib bladder cancer remain conserv
view pipelin await meaning updat
valuat risk valu share use sum-of-the-part sotp
dcf analysi assum wacc tvgr
result tp increas tp ep estim
tvgr base higher convict abil
busi
continu execut pipelin asset risk
develop
clinical/development pipelin product fail regulatori fda/ema
approv product commerci market product sell well
predict price abl achiev price assumpt
market risk biotech volatil sector
valuat metric
number share
cash hand
engag
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
incyt corp biopharmaceut compani engag
discoveri develop commerci proprietari
therapeut oncolog hematolog dermatolog
price jul rate neutral target price analyst evan seigerman
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky upsid case valuat base fda
approv itacitinib steroid-nav gvhd pemigatinib
cholangiocarcinoma within next month also assum
grey sky downsid valuat assum fda
approv pemigatinib itacitinib grey sky also assum neg
data readout pemigatinib urotheli cancer also assum
jakafi revenu lower expect
 close
pipelin updat releas posit data readout topic ruxolitinib
vitiligo capmatinib met-mut non-smal cell lung cancer nsclc also
gain fda approv ruxolitinib gvhd may expect file nda
capmatinib novarti partner receiv royalti sale
pemigatinib cholangiocarcinoma updat also expect
compani also expect result trial ruxolitinib phase
steroid-refractori gvhd trial itacitinib steroid-nav gvhd
model adjust increas tvgr base higher convict
abil replenish cash flow cash hand engag busi
develop continu execut pipelin asset maintain estim
jakafi minim increas jakafi outer year account lower eros
asset model except topic ruxolitinib estim launch slightli
increas estim topic ruxolitinib increas po vitiligo given
posit data releas figur chang overal revenu
due entir inclus mileston payment non-gaap
revenu report compani
figur incyt quarterli annual ep usd
profit loss tax
cog revenu
 revenu
sg revenu
valuat use discount rate fulli dilut share believ
discount rate reflect risk futur cash flow year
experi commerci jakafi view best-in-class product
current minim near-term competit threat assum lower wacc
confid abil market commerci jakafi assign
termin growth free cash flow beyond forecast period increas
tvgr base higher convict abil replenish cash flow
cash hand engag busi develop continu execut pipelin
sotp dcf analysi base sotp dcf primarili driven valuat sale
jakafi see figur valu ww olumi royalti
topic ruxolitinib increas po vitiligo given posit data
pemigatinib bladder cancer estim po
cholangiocarcinoma po valu itacitinib po iclusig
po combin unalloc corpor expens
net cash sotp dcf valu
compani mention price
